Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CET

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
01/19 MERCK KGAA : Darmstadt, Germany, Licenses Four Oncology Research and Development..
01/19 MERCK KGAA : Darmstadt, Germany Licenses Four Oncology Research and Development ..
01/14 VERTEX PHARMACEUTICALS INCORPORATED : Merck expands oncology portfolio with four..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Announces Upcoming Presentation at the J.P..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Patent Issued for Methods of Regioselectiv..
01/11 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Entry into a Material ..
01/11 VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement (fo..
01/11 VERTEX PHARMACEUTICALS INCORPORATED : Merck KGaA, Darmstadt, Germany Licenses Fo..
01/09 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Results of Operations ..
01/09 VERTEX PHARMACEUTICALS INCORPORATED : INC / MA Results of Operations and Financi..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/20 Concert Pharma's CTP-656 an Orphan Drug for cystic fibrosis; shares up 8% pre..
01/17 Concert Pharma to add additional step in mid-stage study of CF candidate CTP-..
01/13 2016 : A Record Year
01/12 Vertex And German Merck Find Their Perfect Fit
01/12 JPMorgan Day Three Roundup - Trump Reminds The Sector Who's In Charge
Advertisement
Financials ($)
Sales 2016 1 695 M
EBIT 2016 237 M
Net income 2016 -131 M
Finance 2016 502 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 106,32
EV / Sales 2016 11,6x
EV / Sales 2017 9,35x
Capitalization 20 182 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,4 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..10.45%20 182
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
CELGENE CORPORATION-2.67%87 334
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
More Results